Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo

Epstein-Barr virus–positive (EBV-positive) B-cell lymphomas are common in immunocompromised patients and remain an unmet medical need. Here we report that MDM2 inhibitors (MDM2is) navtemadlin and idasanutlin have potent in vivo activity in EBV-positive B-cell lymphoma established in immunocompromise...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoshan, Zhang, Ran, Ren, Chenghui, Xu, Yi, Wu, Shuhong, Meng, Carrie, Pataer, Apar, Song, Xingzhi, Zhang, Jianhua, Yao, Yixin, He, Hua, Chen, Huiqin, Ma, Wencai, Wang, Jing, Meric-Bernstam, Funda, Champlin, Richard E., Heymach, John V., Rooney, Cliona M., Swisher, Stephen G., Vaporciyan, Ara A., Roth, Jack A., You, M. James, Wang, Michael, Fang, Bingliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945299/
https://www.ncbi.nlm.nih.gov/pubmed/34861697
http://dx.doi.org/10.1182/bloodadvances.2021006156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945299/
https://www.ncbi.nlm.nih.gov/pubmed/34861697
http://dx.doi.org/10.1182/bloodadvances.2021006156

Ejemplares similares